Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
During the past 11 years, the highest 3-Year average Revenue per Share Growth Rate of Outlook Therapeutics was -31.30% per year. The lowest was -39.20% per year. And the median was -37.20% per year.
Competitive Comparison of Outlook Therapeutics's 3-Year Revenue Growth Rate
For the Biotechnology subindustry, Outlook Therapeutics's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Outlook Therapeutics's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Outlook Therapeutics's 3-Year Revenue Growth Rate distribution charts can be found below:
* The bar in red indicates where Outlook Therapeutics's 3-Year Revenue Growth Rate falls into.
Outlook Therapeutics 3-Year Revenue Growth Rate Calculation
This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
Outlook Therapeutics (NAS:OTLK) 3-Year Revenue Growth Rate Explanation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.
Outlook Therapeutics 3-Year Revenue Growth Rate Related Terms
Thank you for viewing the detailed overview of Outlook Therapeutics's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OTLK has been successfully added to your